Lumida
/AFYA
⌘K
Afya Ltd

Afya Ltd

AFYA
$13.89USD+2.36%+0.32 today

MARKET CAP

1.3B

P/E (TTM)

FWD P/E

DAY RANGE

$14 – $14

52W RANGE

$13
$16

The case for & against

Bull & Bear analysis

Bearish

Afya Limited (NASDAQ: AFYA) is a prominent player in the Brazilian education sector, specializing primarily in medical training and healthcare education. The company operates across three main segments: undergraduate medical programs, continuing education, and medical practice solutions, and has established itself as a leader aiming to enhance healthcare proficiency through education. Afya’s integrated ecosystem, comprising various educational resources, positions it well within the rising demand for skilled healthcare professionals in Brazil, catering to a broad base of students and medical practitioners.

Bull says

  • Q2 revenue R$187.8M grew 10.9% YoY; EPS R$0.43 vs R$0.40.
  • Net income climbed 22.6% to R$38.9M.
  • 26K medical students enrolled (+14% YoY) supports demand.
  • R$64.3M operating cash flow and R$1.2B cash bolster liquidity.
  • Acquisition adds 60 medical seats, enhancing competitive position.
  • Shares ~19% undervalued; high earnings and dividend yield.

Bear says

  • FY26 revenue guidance R$750.2–778.7M trails R$781.6M consensus.
  • Higher operating costs in continuing ed weigh on margins.
  • Analyst rating cut from buy to hold; sentiment weakens.
  • Elevated leverage risk and low liquidity strain finances.
  • Declining B2B engagement and user retention volatility persist.
  • OECD Pillar 2 tax changes could increase operating expenses.

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 08-26-2026neutral

Transcript signals

Bull points

  • Forward-looking statements can be related to future events, future financial or operating performance, known and unknown risks, uncertainties, and other factors that may cause AFIA's actual results to differ materially from those contemplated by these forward-looking statements.

Bear points

  • These risks include those more fully described in our filings with the Securities and Exchange Commission.
Read full transcript analysis ›